Maxus Mining Announces Closing of Flow Through Private Placement

(CNSX:MAXM.CN),(Boerse Frankfurt – Freiverkehr:R7V), VANCOUVER, British Columbia, Nov. 07, 2025 (GLOBE NEWSWIRE) — Maxus Mining Inc. (“Maxus” or the “Company”) (CSE: MAXM | FRA: R7V), is pleased to announce the closing of its non-brokered private placement, announced October 29, 2025, for an aggregate of 2,364,091 flow-through shares of the Company (each, a “FT Share“) at […]

Maxus Mining Announces Closing of Flow Through Private Placement

Maxus Mining Announces Closing of Flow Through Private Placement GlobeNewswire November 07, 2025 VANCOUVER, British Columbia, Nov. 07, 2025 (GLOBE NEWSWIRE) — Maxus Mining Inc. (“Maxus” or the “Company”) (CSE: MAXM | FRA: R7V), is pleased to announce the closing of its non-brokered private placement, announced October 29, 2025, for an aggregate of 2,364,091 flow-through

Furniture Row and Denver Mattress Co. Celebrate Their Grand Opening in West Jordan, UT

Furniture Row and Denver Mattress Company are proud to announce the grand opening of their newest location in West Jordan, Utah, expanding their presence in the Salt Lake Valley. Located at 6054 W 7800 S, the new showroom brings the community an innovative shopping experience with a wide selection of quality furniture, mattresses, and home

New England Realty Associates LP Announces Fourth-Quarter Distribution on Class A Units and Depositary Receipts

On December 31, 2025, New England Realty Associates Limited Partnership (NYSE MKT: NEN) will make its quarterly distribution to its Class A Limited Partners and holders of Depositary Receipts of record as of December 16, 2025. The quarterly distribution per Class A Limited Partnership Unit will be $12.00 per Unit. The quarterly distribution per Depositary

ROSEN, A LEADING AND RANKED FIRM, Encourages Marex Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRX

NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marex Group plc (NASDAQ: MRX) between May 16, 2024 and August 5, 2025, both dates inclusive (the “Class Period”), of the important December 8, 2025 lead plaintiff deadline. SO WHAT: If you

ROSEN, A LEADING AND RANKED FIRM, Encourages Marex Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRX

ROSEN, A LEADING AND RANKED FIRM, Encourages Marex Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRX GlobeNewswire November 07, 2025 NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marex Group plc (NASDAQ: MRX)

Rosen Law Firm Encourages Nidec Corporation Investors to Inquire About Securities Class Action Investigation – NJDCY

https://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.jpg Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Nidec Corporation (OTC: NJDCY) resulting from allegations that Nidec Corporation may have issued materially misleading business information to the investing public. So What: If you purchased Nidec Corporation securities you may be

Notice – JACK MARKS and CNSX MARKETS INC. and ONTARIO SECURITIES COMMISSION, File No. 2025-11

A case management hearing in the above-named matter is scheduled to be heard on November 11, 2025, at 11:30 a.m. by videoconference. Members of the public may observe the hearing by videoconference, by selecting the “View by Zoom” link on the Tribunal's hearing schedule, atcapitalmarketstribunal.ca/en/hearing-schedule Registrar, Governance & Tribunal SecretariatOntario Securities Commission Subscribe to notices

Chicago Rivet & Machine Co. Announces Third Quarter Results of Operations

Chicago Rivet & Machine Co. (NYSE: CVR) today announced results for the third quarter of 2025 as summarized below: CHICAGO RIVET & MACHINE CO.Summary of Consolidated Results of OperationsFor the Three and Nine Months Ended September 30 Third Quarter First Nine Months 2025 2024 2025 2024Net sales $7,360,284 $6,969,921 $21,903,997 $22,882,579Income (loss) before income taxes

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

(NASDAQ:REPL), WOBURN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that biomarker data and updated clinical data from the IGNYTE clinical trial of RP1 plus nivolumab was presented as a late-breaking abstract during an oral session at

Scroll to Top